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Background: Cisplatin-based chemoradiotherapy (CRT) has been a
standard treatment for patients with locally advanced esophageal
cancer. However, cisplatin is associated with significant toxicity. We
conducted a phase II clinical trial of concurrent paclitaxel, carbo-
platin, and radiation with or without surgery as an alternative to the
standard cisplatin-based CRT for localized and metastatic esopha-
geal cancer.
Methods: Fifty patients with esophageal cancer were enrolled: 16
patients with stage II, eight patients with stage III, and 26 patients
with stage IV disease. Two thirds (67%) of patients had adenocar-
cinoma and one third (33%) with squamous histology. Patients with
resectable disease were treated with paclitaxel 30 mg/m2, twice
weekly for 10 doses, carboplatin AUC (area under the curve) 1.5
weekly for five doses; and concurrent radiation, 1.8 Gy/day, for a
total of 45 Gy, followed by esophagectomy. Without surgery,
patients received an additional dose each of paclitaxel and carbo-
platin with concurrent radiation for a total of 50.4 Gy, followed by
two consolidation cycles of paclitaxel (200 mg/m2) and carboplatin
(AUC 6).
Results: During CRT, common stage III/IV toxicities included
nausea/emesis (19%), esophagitis (9%), and neutropenia (4%). For
consolidation chemotherapy, neutropenia (23%), neuropathy (8%)
and nausea/emesis (4%) were the most common stage III/IV side
effects. After CRT, 26% had a complete response, 17% had a partial
response, and 41% had stable disease. Ninety-one percent of patients
had clinical improvement of dysphagia. With a median follow-up of
32 months, the median survival was 12 months for patients with
metastatic disease, 44 months for localized disease treated with
esophagectomy, and 44 months for localized disease treated with
definitive CRT.
Conclusions: The regimen of paclitaxel, carboplatin, and radiation
with or without surgery is well tolerated with promising efficacy for
patients with esophageal cancer.
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The prognosis for patients with esophageal cancer is poor.In 2006, it is estimated that there will be 14,450 new cases
and 13,770 deaths from esophageal cancer in the United
States.1 Of particular concern is the fact that the incidence of
lower esophageal or gastroesophageal adenocarcinoma has
increased faster than any other malignancies in North Amer-
ica.2 A majority of the cases are unresectable or metastatic at
presentation, and only a minority of patients with resectable
disease can be cured with surgery alone.3 The 3-year survival
rate for patients with apparently localized esophageal cancer
after chemoradiotherapy (CRT) and/or surgery has typically
been in the range of 15% to 30%.4 Multiple randomized trials
of surgery with or without adjuvant chemoradiation have
yielded mixed results.5–10 Nevertheless, concurrent CRT has
become the standard of care for patients with locally ad-
vanced disease based on the results of the landmark study
conducted by the Radiation Therapy Oncology Group
(RTOG 85-01).11,12 In all these trials, cisplatin-based regi-
mens were employed. However, cisplatin is cumbersome to
use as prolonged intravenous hydration is required. In addi-
tion, cisplatin is a relatively toxic drug with a high incidence
of nausea/emesis and renal dysfunction. In the treatment of
non-small cell lung cancer (NSCLC) and ovarian cancer,
carboplatin has gradually replaced cisplatin as the platinum of
choice. In addition, carboplatin, given together with pacli-
taxel, appears to have anticancer activity in esophageal can-
cer.13,14 We have demonstrated the safety and efficacy of
twice-weekly paclitaxel, weekly carboplatin, and concurrent
radiation for stage III NSCLC.15 Thus, we extended this
regimen to the treatment of esophageal cancer.
PATIENTS AND METHODS
Eligibility
Patients must have histologically proven adenocarci-
noma or squamous cell carcinoma of the esophagus including
the gastroesophageal junction. Patients must have stage II to
IV disease according to the Manual for Staging of American
Joint Committee on Cancer, Fourth Edition. Initial staging
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procedures included computed tomography scans of the chest
and abdomen and upper gastrointestinal endoscopy with an
endoscopic ultrasound scan. If there was no apparent meta-
static disease, patients then underwent positron emission
tomography scan and laparoscopic exploration to rule out
occult metastases. No previous chemotherapy or radiation
was allowed. Patients must have an Eastern Cooperative
Oncology Group (ECOG) performance status of 0 to 2.
Adequate hematologic parameters (white blood cell count
3500/l, platelets 100,000/l), and hepatic (total biliru-
bin 2.0 mg/dl) and renal functions (calculated creatinine
clearance of 40 ml/min) were required. The study was
approved by the Institutional Review Board, and all patients
gave written informed consents.
Treatment Plan
The treatment schema is shown in Figure 1. Patients
with stage II disease were considered candidates for esoph-
agectomy unless they refused surgery. All the patients under-
went CRT consisting of paclitaxel, carboplatin, and concur-
rent radiation as initial therapy. In the setting of metastatic
disease, CRT was justified by the fact that a majority of
patients presented with dysphagia and/or odynophagia that
required palliation. Paclitaxel, at a dose of 30 mg/m2, was
administered intravenously over 1 hour twice weekly for a
total of 10 and 11 doses, respectively, for patients planned for
surgery or no surgery. Premedications, including dexameth-
asone, before administration of low-dose paclitaxel were not
necessary to prevent allergic reactions if there was no reac-
tion observed after the first dose of paclitaxel.16 Carboplatin,
at an area under the curve (AUC) of 1.5 mg/ml/min, was
given intravenously over 30 minutes weekly for a total of
five and six doses, respectively, for surgical or nonsurgical
candidates.
Concurrent chest irradiation was delivered using mega-
voltage equipment with energies of 6 MV or higher. Simu-
lation was performed with the primary tumor and enlarged
nodes as determined by computed tomography, positron
emission tomography, or endoscopic ultrasonography, and
they were included as the gross tumor volume (GTV). The
superior and inferior borders of the radiation field were 5 cm
beyond the primary tumor. The lateral, anterior, and posterior
borders of the field were2 cm beyond GTV. Beam arrange-
ments were usually anteroposterior/posteroanterior with the
use of one or two oblique or lateral fields to keep the maximum
dose to the spinal cord 45 Gy. Patients were treated 5 days
per week at a daily dose of 1.8 Gy/day prescribed to the
isocenter. The total dose of radiation was 45 Gy for surgical
and 50.4 Gy for nonsurgical patients.
Four to 6 weeks after CRT, patients underwent esoph-
agectomy using either the transhiatal or thoracoabdominal
approach with cervical anastomosis, if they initially presented
with stage II disease and agreed to proceed with surgery. For
patients who did not undergo esophagectomy, they received
two cycles of consolidation chemotherapy consisting of pac-
litaxel, 200 mg/m2, and carboplatin, AUC 6, given 3 weeks
apart.
Evaluation of Toxicity and Efficacy
Toxicity was graded according to the Common Toxic-
ity Criteria, Version 2.0, of National Cancer Institute. Chest
and abdominal computed tomography scans and endoscopic
ultrasound scans were obtained to assess tumor status, es-
pecially the depth of invasion of the primary tumor and
mediastinal lymphadenopathy, 4 weeks after completing the
induction CRT, and 4 to 6 weeks after consolidation chemo-
therapy. Tumor response was measured according to the
criteria of World Health Organization.17 For localized dis-
ease, a complete response must also meet the pathologic
criteria of no evidence of residual disease upon esophagec-
tomy or endoscopic biopsy.
Statistics
This phase II trial was originally designed using a two-
stage minimax approach as proposed by Simon.18 If a re-
sponse rate of 35% to CRT was observed with a minimum of
23 patients, an additional 15 patients would be enrolled.
Subsequently, an additional 12 patients were enrolled, for a
FIGURE 1. Treatment schema.
CRT, chemoradiotherapy.
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total of 50 patients, in an attempt to increase the number of
patients with localized disease. Overall survival probability
was estimated using the method of Kaplan-Meier.19 The date
of starting treatment was the reference date for estimating
survival for each patient.
RESULTS
Patient Characteristics
Within a period of 4.5 years, 50 consecutive eligible
patients with esophageal cancer were enrolled at a single
institution. The patient characteristics are shown in Table 1.
The median age was 60 years with a range of 38 to 85 years.
Eighty-eight percent of the patients were men and 98% had
an ECOG performance status of 0–1. Five patients (10%) had
stage IIA (T2–3N0), 11 patients (22%) stage IIB (T1–2N1),
eight patients (16%) stage III (T3–4N1), and 26 patients
(52%) stage IV (TxNxM1) diseases. Among the 26 patients
with metastatic disease, 60% had liver metastasis, 20% had
lung metastasis, and 12% had celiac node metastasis. Sixty-
seven percent of the patients had adenocarcinoma and 33%
had squamous carcinoma.
Toxicities and Compliance to Planned
Treatment
Of 50 patients enrolled in the study, 44 patients (88%)
completed at least 90% of the planned induction CRT and 48
patients were assessable for acute toxicities. Two patients
withdrew voluntarily from the study early during CRT and
were deemed not assessable. The most common grade III and
IV toxicities are shown in Table 2. During induction CRT,
nausea and vomiting (19%) were the most frequent grade
III/IV toxicities, followed by esophagitis (9%) and neutrope-
nia (4%). Thirty patients went on to receive at least one cycle
of consolidation chemotherapy. Neutropenia (23%) was the
most common grade III/IV toxicity after consolidation che-
motherapy. Grade III/IV neuropathy and nausea/emesis oc-
curred in only 7% and 3% of patients, respectively. Ten
patients received neoadjuvant CRT: two refused surgery and
eight underwent esophagectomy. Among the patients who
had undergone esophagectomy, two developed esophageal
stricture, one had a bronchoesophageal fistula, and another
patient had a perforation of conduit. No treatment-related
death was encountered during CRT, consolidation chemo-
therapy, or surgery. Two patients died shortly after complet-
ing CRT due to progression of metastatic disease.
Assessment of Efficacy
Forty-six patients were assessable for responses. As
mentioned above, two patients dropped out early in treatment
and two died within 2 months after commencement of treat-
ment. Following CRT, there were 12 (26%) patients with
complete response, eight (17%) with partial response, 19
(41%) with stable disease, and nine (20%) with progressive
disease as shown in Table 3. Consolidation chemotherapy did
not appear to achieve additional responses. Among the eight
patients who underwent surgical resection, pathologic com-
plete response was observed in six patients. Based on report
by patients, relief of dysphagia was achieved in 41 (91%) of
45 patients who presented with symptoms of dysphagia.
Patients were followed until death or at the time of this
report. The duration of follow-up ranged from 5 to 64 months
with a median of 32 months. As assessed by Kaplan-Meier
analysis, overall survival of each of the three subgroups is
shown in Figure 2. The median survivals were 44 months,
44 months, and 12 months, respectively, for patients with
localized disease treated with CRT and consolidation chemo-
therapy (n  16), patients with localized disease treated with
CRT plus surgery (n  8), and patients with metastatic
TABLE 2. Common Grade III/IV Toxicities, No. (%)
Induction chemoradiation (n  48)
Nausea/emesis 9 (19)
Esophagitis 4 (9)
Neutropenia 2 (4)
Consolidation chemotherapy (n  30)
Neutropenia 7 (23)
Neuropathy 2 (7)
Nausea/emesis 1 (3)
Surgical complications (n  8)
Esophageal stricture 2 (25)
Bronchoesophageal fistula 1 (15)
Perforation of conduit 1 (15)
Operation mortality 0 (0)
TABLE 1. Patient Characteristics
No. of patients 50
Median age, y (range) 60 (38–85)
Gender, no. (%)
Male 44 (88)
Female 6 (12)
Performance status, no. (%)
0 19 (37)
1 30 (61)
2 1 (2)
Stage, no. (%)
IIA (T2–3, N0) 5 (10)
IIB (T1–2, N1) 11 (22)
III (T3, N1; T4, N0-1) 8 (16)
IV (TxNxM1) 26 (52)
Histologic type, no. (%)
Adenocarcinoma 34 (67)
Squamous carcinoma 16 (33)
TABLE 3. Responses to Induction CRT (n  46)
Response No. (%) of Patients
Complete response 12 (26)
Partial response 8 (17)
Stable disease 19 (41)
Progression of disease 9 (20)
Relief of dysphagia 41 (91)
CRT, chemoradiotherapy.
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disease treated with CRT and consolidation chemotherapy
(n  26). Three-year overall survival rates were 60%, 60%
and 14%, respectively, for the corresponding groups. The
distribution of disease stages among patients who underwent
surgery versus patients with localized disease and treated
with definitive CRT alone is shown in Table 4. All the
patients in the surgical group had stage II disease, whereas
only 50% of the nonsurgical group had stage II disease.
DISCUSSION
The standard treatment for esophageal cancer remains
to be refined. Historically, the outcome for patients with
esophageal cancer has been dismal.3 Patients with resectable
disease who are treated with surgery alone have a high rate of
distant and locoregional failure, despite apparently complete
resection. Addition of chemoradiotherapy resulted in con-
flicting results.5–10 The role of surgery after CRT has also
been called into question even for potentially resectable
disease.20,21 For locally advanced esophageal cancer, cispla-
tin-based chemoradiation has been considered the standard of
care in the past 15 years since the publication of the RTOG
85-01 randomized trial.11,12 In this trial, patients with squa-
mous carcinoma or adenocarcinoma of the esophagus, T1-
3N0-1M0, were treated with radiation of 64 Gy in 32 frac-
tions or radiation of 50 Gy in 25 fractions plus cisplatin and
5-fluorouracil. After 5 years of follow-up, the overall survival
rate for patients with CRT was 26% compared with 0% with
radiation alone. The outlook for metastatic disease remains
grim despite the advent of new anticancer agents.4 With the
availability of new anticancer drugs in the past decade and the
rapid increase in the incidence of gastroesophageal junction
adenocarcinoma, there is an urgency to test novel treatments
for this devastating disease.
Although cisplatin-based therapy is a mainstay treat-
ment for esophageal cancer in the setting of locally advanced
or metastatic disease, it is a drug that is cumbersome to use
with relatively high-rate of toxicity. In the landmark trial of
RTOG 85-01, only 68% of patients received cisplatin and
5-fluorouracil as planned and 10% had life-threatening toxic
effects.12 Carboplatin and paclitaxel have gradually replaced
cisplatin-based regimens in the treatment of NSCLC.22,23
Carboplatin and paclitaxel are active in treating esophageal
cancer as demonstrated in phase I and II clinical trials.13,14
The safety and efficacy of twice-weekly paclitaxel, weekly
carboplatin, and concurrent radiotherapy have been demon-
strated at our institution for stage III NSCLC.15 Paclitaxel
was given twice weekly instead of weekly to optimize its
radiosensitizing effect. This regimen was indeed well toler-
ated by patients with esophageal cancer and with promising
efficacy. Of the 50 patients entered into the trial, 88% of the
patients had completed at least 90% of the planned chemo-
therapy and radiation. Nausea and emesis were the most
common grade III/IV toxicity occurring in 19% of the pa-
tients. Grade III/IV neutropenia and esophagitis occurred in
less than 10% of patients. On the other hand, 90% of the
patients experienced rapid improvement in their presenting
obstructive symptoms within 2 weeks of initiation of the
therapy. This profile of toxicity compared most favorably
with cisplatin-based chemoradiation.5–12
The efficacy of this CRT regimen is remarkable as well,
especially in patients with localized disease. Although it was
a small study, the overall median survival and 3-year survival
rate of patients with localized disease treated with CRT
followed by consolidation chemotherapy were, respectively,
44 months and 60%. In clinical trials that have been
reported to date on locally advanced esophageal cancer, the
median survival typically has ranged from 12 to 18 months,
and the 3-year survival rate ranged from 15% to 30%.4 In a
randomized trial, recently reported by Stahl et al.,21 compar-
ing CRT with or without surgery for squamous cell carci-
noma of the esophagus, only a subgroup analysis of respond-
ers to CRT revealed a 3-year survival rate of 55%. The
promising survival results from our trial cannot be explained
by salvage therapy, as second-line treatments for refractory or
relapsed esophageal cancer remain poor.4
In this trial, all the patients, regardless of disease stage,
were treated with CRT. Our rationale was that most of the
patients with esophageal cancer presented with, or eventually
would develop, a certain degree of obstructive symptoms,
and, hence, it would be reasonable to provide local therapy to
palliate symptoms and improve nutritional intake. This is
particularly true for patients who are not surgical candidates.
However, the benefit of providing neoadjuvant CRT is still
debatable.5–10 Conversely, the value of surgery after CRT for
localized disease is controversial, as shown in the two recent
FIGURE 2. Kaplan-Meier plots of overall survival among
three groups of patients.
TABLE 4. Distribution of Disease Stages among Patients
Who Had Surgery  CRT versus CRT Alone
Stage
No. of Patients
CRT  Surgery CRT Alone
IIa 3 1
IIb 5 7
III 0 8
Total 8 16
CRT, chemoradiotherapy.
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randomized trials.20,21 Therefore, at our institution, we advo-
cate treating locally advanced disease (stages II and III) with
definitive CRT employing the regimen reported here. Finally,
for patients with metastatic diseases, we recommend up-front
chemoradiation for selected patients with dysphagia and good
performance status.
In conclusion, the regimen of concurrent paclitaxel,
carboplatin, and radiation is promising for treatment of lo-
calized esophageal cancer. We propose to compare this reg-
imen with the traditional cisplatin-based regimen for patients
with esophageal cancer needing definitive CRT in a future
clinical trial.
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